carboplatin + cisplatin

This refers to the platinum-based chemotherapy component (either carboplatin or cisplatin) utilized in a Phase II clinical trial (NCT06177925) conducted by Nanfang Hospital, Southern Medical University. In this treatment protocol, these agents are used as first-line therapy for extensive-stage oligometastatic small cell lung cancer (ES-SCLC) in combination with etoposide, the anti-PD-L1 monoclonal antibody adebrelimab, and concurrent radiotherapy. Carboplatin and cisplatin are small molecule platinum compounds that exert their antineoplastic effects by forming intra-strand and inter-strand DNA crosslinks, which inhibit DNA replication and transcription, ultimately leading to cell cycle arrest and apoptosis. In the specific trial context, carboplatin is dosed at AUC=5 and cisplatin at 75 mg/m2, serving as interchangeable platinum options during the induction and concurrent chemoradiotherapy phases.

Brand names

ParaplatinPlatinol

Other names

Carboplatin/Cisplatin